Interim Results Of A Phase 1b/2a Study Evaluating The Nano Pharmaceutical Crlx101 With Bevacizumab (Bev) In The Treatment Of Patients (Pts) With Refractory Metastatic Renal Cell Carcinoma (Mrcc).
JOURNAL OF CLINICAL ONCOLOGY（2014）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要